Canada's CDRD attracts Pfizer funding
Global drug giant Pfizer's Canadian subsidiary has committed $1.0 million to the Centre for Drug Research and Development (CDRD) to create the Pfizer-CDRD Innovation Fund. This innovation fund aims to fast-track the commercialization of some of British Columbia's most promising academic research projects into high-value medicines that form the basis for new companies or licensing opportunities.
The Pfizer-CDRD Innovation Fund is a unique public-private partnership, and Pfizer Canada is the first international research-based pharmaceutical company to establish an innovation fund at the CDRD to advance commercialization opportunities, the firm claims.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze